Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

sirolimus protein-bound particles

sirolimus protein-bound particles
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Fyarro SUSPENSION, INTRAVENOUS 100 mg      
Comments:

Restricted to oncologist use in the hospital outpatient setting. May also administer as a PAP.

 

 

 

Reviewed: November 2024

 

Sirolimus protein-bound particles (FYARRO) Spotlight.pdf 

Last updated: Dec. 16, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved